Enlivex Therapeutics (NASDAQ:ENLV), trading on the NASDAQ under the symbol ENLV, is a clinical‐stage biotechnology company specializing in cellular immunotherapy to address life‐threatening acute organ dysfunction. The company’s lead product candidate, Allocetra™, is designed to modulate the innate immune response, with a primary focus on treating sepsis, acute respiratory distress syndrome (ARDS) and other cytokine‐mediated conditions. By harnessing the body’s own immune cells, Enlivex aims to restore homeostasis and reduce the high morbidity and mortality rates associated with these critical illnesses.
Allocetra™ is based on allogeneic mononuclear enriched white blood cells collected from screened healthy donors. The company’s proprietary manufacturing process entails ex vivo reprogramming of donor cells to induce an immunomodulatory phenotype. Enlivex has advanced this platform through multiple Phase 1 and Phase 2 clinical trials, demonstrating safety, tolerability and promising efficacy signals in patients with sepsis and other acute conditions. In parallel, the company is exploring potential applications in graft‐versus‐host disease (GvHD) and other inflammatory disorders where uncontrolled immune activation plays a central role.
Founded in 2005 and headquartered in Ness Ziona, Israel, Enlivex maintains operations in the United States to support its global clinical development and regulatory strategy. The company collaborates with leading academic medical centers and contract research organizations across North America, Europe and Asia. These partnerships have facilitated patient enrollment in key markets and enabled Enlivex to expand its trial footprint into intensive care units and transplant centers worldwide.
Enlivex is guided by a seasoned executive team and board of directors with extensive experience in biotechnology, immunotherapy and pharmaceutical development. Under the leadership of its chief executive officer and a management team seasoned in cell therapy and regulatory affairs, the company continues to advance its mission of delivering innovative immunomodulatory treatments for patients facing severe, life‐threatening conditions.
